Sakar Healthcare
Sakar Healthcare Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Sakar Healthcare Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Sakar Healthcare Ltd trades at a P/E of 60.02× and P/B of 5.65×.
Valuation
Profitability
Growth
Financial Health
Sakar Healthcare Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Sakar Healthcare Ltd, switchable between annual and quarterly views, consolidated or standalone.
Sakar Healthcare Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,844.52 Cr and reported EPS of ₹13.73.
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 95 | 128 | 133 | 153 | 178 | 252 |
| Other Income | 1 | 2 | 5 | 3 | 1 | 2 |
| Total Income | 96 | 130 | 138 | 157 | 179 | 254 |
| Cost of Goods Sold (COGS) | 51 | 74 | 74 | 84 | 82 | 123 |
| Gross Profit | 44 | 54 | 60 | 70 | 95 | 128 |
| +Operating Expenses | 21 | 24 | 27 | 31 | 46 | 60 |
| EBITDA | 23 | 29 | 33 | 38 | 50 | 69 |
| +Non-Operating Expenses | 11 | 13 | 21 | 26 | 29 | 31 |
| Profit Before Tax (PBT) | 13 | 19 | 17 | 16 | 22 | 40 |
| +Tax Expense | 3 | 4 | 4 | 4 | 4 | 9 |
| Profit After Tax (PAT) | 11 | 15 | 13 | 12 | 18 | 30 |
| Earnings Per Share (EPS) | 6.84 | 8.73 | 6.70 | 5.37 | 7.97 | 13.70 |
| Diluted Shares Outstanding (Nos.) | 2 | 2 | 2 | 2 | 2 | 2 |
| +Additional Disclosures | 134 | 186 | 194 | 224 | 239 | 337 |
| Sales Growth % | — | 35.35 | 4.00 | 14.99 | 15.80 | 41.76 |
| YoY Sales Growth % | — | 35.35 | 4.00 | 14.99 | 15.80 | 41.76 |
| Material Cost % | 55 | 57 | 55 | 55 | 54 | 53 |
| Employee Cost % | 14 | 12 | 13 | 13 | 18 | 15 |
| Other Cost % | 8 | 7 | 7 | 8 | 8 | 8 |
| OPM % | 24 | 23 | 25 | 25 | 28 | 27 |
| Tax % | 19 | 20 | 24 | 27 | 19 | 23 |
| Profit Growth % | — | 42.10 | -15.95 | -8.53 | 49.96 | 74.18 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 15 | 20 | 18 | 20 | 29 | 45 |
Sakar Healthcare segment analysis: revenue and profit mix.
Disclosed business segments at Sakar Healthcare with their share of revenue and profit, switchable between consolidated and standalone reporting.
Sakar Healthcare discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Sakar Healthcare Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Sakar Healthcare Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Sakar Healthcare Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust quarterly profit growth of 93.80% indicates strong operational performance.
Healthy quarterly sales growth of 28.20% reflects increasing market demand.
Strong operating profit margin of 27.30% highlights efficient cost management.
Low debt-to-equity ratio of 0.30 ensures a sound, flexible financial structure.
Diversified product portfolio and global export presence across 50+ countries.
What can break it.
Low Return on Equity (ROE) at 6.48% suggests insufficient shareholder returns.
Return on Capital Employed (ROCE) at 8.54% indicates capital inefficiency.
High P/E ratio of 44.97 suggests potential overvaluation compared to earnings.
Absence of dividend yield (0.00%) may deter income-focused investors.
Negative 5-year Free Cash Flow CAGR of -20.56% is a concern.
What would change my mind.
Trim if P/E re-rates above 78. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 22.24. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Sakar Healthcare Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Sakar Healthcare Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Sakar Healthcare Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Sakar Healthcare Ltd — derived from the live tape, not yesterday's close.
Sakar Healthcare Ltd last traded at ₹824.1 with an intraday range of ₹810–₹841.5 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹824.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 903.40 | +79.30 | +9.62% |
| R3 | 871.90 | +47.80 | +5.80% |
| R2 | 856.70 | +32.60 | +3.96% |
| R1 | 840.40 | +16.30 | +1.98% |
| PIVOT | 825.20 | 1.10 | 0.13% |
| CURRENT | 824.10 | — | — |
| S1 | 745.90 | -78.20 | -9.49% |
| S2 | 777.40 | -46.70 | -5.67% |
| S3 | 793.70 | -30.40 | -3.69% |
| S4 | 808.90 | -15.20 | -1.84% |
SAKAR is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 810 ~ 841.5
Trading Inside opening range
Sakar Healthcare Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Sakar Healthcare Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Sakar Healthcare Ltd stood at 62.9% of traded volume, against a 20-day average of 45.6%.
Sakar Healthcare announcements: results, concalls, ratings, M&A.
Filings Sakar Healthcare sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Sakar Healthcare files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 72 documents below.
Reply to Clarification- Financial results
The Exchange had sought clarification from Sakar Healthcare Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI…
Analysts/Institutional Investor Meet/Con. Call Updates
Sakar Healthcare Limited has informed the Exchange about Transcript
General Updates
Sakar Healthcare Limited has informed the Exchange about Sakar enters it s 40th agreement signed with Zydus Lifesciences to cater oncology products…
Disclosure under SEBI Takeover Regulations
Sanjay S. Shah has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Analysts/Institutional Investor Meet/Con. Call Updates
Sakar Healthcare Limited has informed the Exchange about Link of the audio recording of Conference call with all the participants held on 15th May…
Investor decks & rating reports.
Sakar Healthcare insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Sakar Healthcare as reported to SEBI — buying and selling signals from the people who know the business best.
Sakar Healthcare insider activity below tracks 2 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Aarsh S. Shah | Insider | 27 Dec 2024 | buy | +1.00 L | ₹2.88 Cr | ₹288.00 |
| Sanjay S. Shah | Insider | 27 Dec 2024 | buy | +1.00 L | ₹2.88 Cr | ₹288.00 |
Sakar Healthcare dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Sakar Healthcare has declared, sequenced by announce and record date.
Sakar Healthcare corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Sakar Healthcare Ltd: business, sector, key facts.
What Sakar Healthcare Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Sakar Healthcare Ltd operates in the Healthcare, listed as NSE: SAKAR.
Sakar Healthcare Limited is an Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a diverse range of pharmaceutical products. Their operations encompass the entire production process, from initial research and development to final product marketing and distribution. The company's commitment to a wide spectrum of therapeutic areas allows them to cater to a broad patient base and market demand.
The company's product portfolio is extensive and includes various dosage forms to accommodate diverse patient needs and treatment preferences. These forms include liquid orals, tablets, capsules, dry powder syrups, dry powder injections, liquid injectables (SVP) in ampoules and vials, lyophilized injections, and oral solid dosages. This breadth of dosage forms allows for flexibility in administration and potentially improved patient compliance.
Sakar Healthcare's product offerings span a considerable number of therapeutic areas, indicating a wide range of medical conditions addressed by their formulations. These areas include antacids, antimalarials, anticoagulants, laxatives, anthelmintics, bronchodilators, anesthetics, antidepressants, sedatives, adrenergics, anti-infectives, diuretics, oxytocics, analgesics, antiemetics, antipsychotics, antifungals, PPIs, anticonvulsants, anti-inflammatories, antihistamines, and multivitamins. This diversified portfolio demonstrates a commitment to serving a wide range of patient needs.
Beyond the domestic Indian market, Sakar Healthcare actively participates in international trade, exporting its products to several key regions globally. These export destinations encompass Southeast Asia, other parts of Asia, various African countries (both Anglophone and Francophone), the Middle East and North Africa (MENA) region, and even the United States. This international reach significantly expands the company's market presence and potential for growth.
Established in 2004 and headquartered in Ahmedabad, India, Sakar Healthcare Limited has a history of providing pharmaceutical solutions. Their integrated approach, encompassing research, development, manufacturing, and marketing, positions them as a significant player within the Indian pharmaceutical industry and beyond, through its international exports. The company's success rests on its broad product portfolio, diverse therapeutic coverage, and global market reach.
Questions investors ask about Sakar Healthcare Ltd (SAKAR).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Sakar Healthcare Ltd (SAKAR)?
The current share price of Sakar Healthcare Ltd (SAKAR) is ₹824.1. Today, the stock has gained by ₹21.05 (2.62%), trading in a range of ₹810 to ₹841.5. The stock opened at ₹810 with a trading volume of 1,04,622 shares.
02Is Sakar Healthcare Ltd stock a good investment for long-term?
Sakar Healthcare Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,844.52 crores, P/E ratio of 60.02, ROE of 10.00%, and ROCE of 8.54%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Sakar Healthcare Ltd stock?
The 52-week high price of Sakar Healthcare Ltd (SAKAR) is ₹0, while the 52-week low is ₹0. Currently trading at ₹824.1, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Sakar Healthcare Ltd stock at the current price?
Whether to buy Sakar Healthcare Ltd stock at ₹824.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 60.02 and P/B ratio of 5.65. Today's performance shows a gain of 2.62%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Sakar Healthcare Ltd and when is the next dividend?
Sakar Healthcare Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹824.1, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Sakar Healthcare Ltd?
Sakar Healthcare Ltd's key financial metrics include: P/E Ratio: 60.02, P/B Ratio: 5.65, ROE: 10.00%, ROCE: 8.54%, Dividend Yield: 0.00%, EPS: ₹13.73, Book Value: ₹145.98, and Debt-to-Equity: 21.74. The company's market cap stands at ₹1,844.52 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Sakar Healthcare Ltd stock performing today in the market?
Sakar Healthcare Ltd stock opened at ₹810 and is currently trading at ₹824.1, showing a gain of ₹21.05 (2.62%). The intraday high is ₹841.5 and low is ₹810. The trading volume stands at 1,04,622 shares, indicating moderate market participation today.
08What is the P/E ratio of Sakar Healthcare Ltd and what does it indicate?
Sakar Healthcare Ltd has a Price-to-Earnings (P/E) ratio of 60.02, which means investors are willing to pay ₹60.02 for every ₹1 of earnings. With an EPS of ₹13.73, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Sakar Healthcare Ltd (SAKAR) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- AHCL (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy